

Contact: Dr. Wei-Sing Chu

**Location:** Rockville, Maryland, USA **Email:** wei-sing.chu@bio-quick.com

**Tel:** 301.625.8102

Website: www.bio-quick.com

### **BIO-QUICK Corporation**

# National Institutes of Health Commercialization Assistance Program (NIH-CAP)

## **Company Overview**

**Industry Sector: Medical Devices** 

**Company Overview:** Bio-Quick is a research and development company focused on improving tissue specimen preservation and processing in processing time, cost-effectiveness, quality, and efficiency for pathological research and diagnosis of diseases, such as cancer.

Target Market(s): Hospitals, clinics, and research labs.

## **Key Value Drivers**

**Technology\*:** The US-FFPE tissue specimen preparation technology can reduce the whole tissue specimen preparation time from 16-48 hr to less than 1 hr, thus it can greatly shorten the turn-around time of cancer diagnosis and makes it possible for standardization of clinical tissue specimen preparation.

**Competitive Advantage:** The US-FFPE technology shares the basic mechanism of the conventional FFPE method, but it reduces the formalin fixation time from several hours down to about 30 minutes. The time required for the succeeding processing steps is also reduced from several hours to less than 1 hour. The US-FFPE technology changes the formalin fixation mechanism and is more molecular friendly than its conventional counterpart.

\*Technology funded by the NCI/NIH and being commercialized under the NIH-CAP

# Management

### Leadership:

Wei-Sing Chu, President and CEO Andrew Ji, Vice President of Business Huiqi He, Chief Scientific Officer Jeffery Ihnen, Legal and IP Counsel

### Consultants, Collaborators, and Scientific Advisory Board:

Paul Nisson, Ph.D. Executive Director, Biomedical Research Institute, MD Jackson Yang, Ph.D. President, Advanced Technology & Research Co. MD Richard Zhao, Ph.D. Professor, Molecular Pathology & Translational Genomics Laboratory, University of Maryland Medical Center. MD Brain Balgley, Ph.D. President & CEO, Bioproximity, LLC. VA Sean Yu, Ph.D. President, BioAstrum, Corp. MD

# Product Development 1Q13 2Q13 3Q13 4Q13 1Q14 2Q14 3Q14 4Q14 Prototype Evaluation 3rd Prototype/Pilot Production